IN THE CLAIMS

1. (original) A crystalline polymorph A of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 6.4 (s), 6.15 (s), 5.69 (s), 4.59 (vs), 4.53 (s), 4.02 (s), 3.71 (vs), 3.08 (s); wherein (vs) = very strong intensity; (s) = strong intensity.

2. (previously presented) A crystalline polymorph A of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claim 1, having an X-ray powder diffraction pattern substantially as depicted in figure 1.

3-20. (cancelled).

21. (previously presented) A process for the manufacture of crystalline polymorph A of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claim 1 wherein a solution of Zolmitriptan in an organic solvent or mixture of organic solvents is cooled, provided that the solution does not contain 1-butanol, anisole, 2-propanol, ethyl methyl ketone, tetrahydrofuran, 1,4-dioxane, or ethyl acetate.

22. (currently amended) A process according to claim 21, wherein an organic solvent is selected from the group consisting of C_1-C_4alkanols, sulfoxides, ~~and/or~~ amides, and~~or~~ mixtures of C_1-C_4alkanols with water.

23. (previously presented) A process according to claim 21, wherein the solution additionally contains a non-solvent selected from alkanes and ethers.

24. (previously presented) A process according to claim 21 in which the solution is cooled from a temperature of about 20° to 100°C down to about –20°C to 10°C.

25. (previously presented) A process for the manufacture of crystalline polymorph A of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claim 1 wherein crystalline Zolmitriptan is suspended, or amorphous Zolmitriptan is dispersed, in an organic solvent, provided that the solvent does not contain 1-butanol, anisole, ethyl methyl ketone, tetrahydrofuran, or 1,4-dioxane.

26. (previously presented) A process according to claim 25, wherein the organic solvent is an alcohol or an acetate.

27-32. (cancelled).

33. (previously presented) A process according to claim 21, wherein seeding is carried out with crystals of the desired crystalline polymorph.

34. (previously presented) A process according to claim 21 in which the solution or dispersion of Zolmitriptan is prepared in situ.

35. (currently amended) A pharmaceutical composition comprising crystalline polymorphic form A~~a crystalline polymorphic form~~ according to claim 1, and a pharmaceutically acceptable carrier.

36. (currently amended) Zolmitriptan containing crystalline polymorphic form A~~a crystalline polymorphic form~~ according to claim 1.

37-38. (cancelled)